AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Small ribosomal subunit protein mS40

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y676

UPID:

RT18B_HUMAN

Alternative names:

28S ribosomal protein S18-2, mitochondrial; 28S ribosomal protein S18b, mitochondrial; Small ribosomal subunit protein bS18b

Alternative UPACC:

Q9Y676; A6NDQ0; Q659G4; Q9BS27

Background:

The Small ribosomal subunit protein mS40, also known as 28S ribosomal protein S18-2, mitochondrial, 28S ribosomal protein S18b, mitochondrial, and Small ribosomal subunit protein bS18b, plays a crucial role in the mitochondrial ribosome. Its primary function is to ensure the proper assembly and function of the ribosome, which is essential for protein synthesis within the cell.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein mS40 could open doors to potential therapeutic strategies. Its pivotal role in protein synthesis makes it an intriguing target for research aimed at addressing mitochondrial diseases and disorders related to protein synthesis.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.